Allergic Rhinitis Improvement in Asthmatic Children After Using Acaricidal Bait: A Randomized, Double-Blind, Cross-Placebo Study

Chen, Ming; Wu, Yulian; Yuan, Shuo; Tang, Mingyu; Zhang, Lei; Chen, Jiande; Li, Luanluan; Wu, Jinhong; Zhang, Jing; Yin, Yong

doi:10.3389/fped.2021.709139

Cited by 6 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported by Kneist et al 1708 . Using a crossover study design, Chen et al 1716 . investigated an acaricide containing bag placed beneath bed mattresses in children with AR and asthma, reporting improved AR symptom scores and disease specific QOL (measured using the RQLQ) for those in the intervention group compared to control.…”

Section: Managementsupporting

confidence: 62%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Section: Managementsupporting

confidence: 62%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

show abstract

“…The studies analyzed had different outcome measures and the measures were tested considering different allergens. House dust mite (HDM) was the most common allergen sensitization and most measures were designed to control HDM exposure [14,15,17,21,23,24,[26][27][28][29][30][31]. Out of the 18 studies, 5 of them had participants with ages ranging from 6 to 16 years old [17,18,24,29,30].…”

Section: Resultsmentioning

confidence: 99%

“…House dust mite (HDM) was the most common allergen sensitization and most measures were designed to control HDM exposure [14,15,17,21,23,24,[26][27][28][29][30][31]. Out of the 18 studies, 5 of them had participants with ages ranging from 6 to 16 years old [17,18,24,29,30]. The general characteristics and findings of these studies are presented in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Avoidance Measures for Patients with Allergic Rhinitis: A Scoping Review

Tomé

Lourenço

2023

Children

View full text Add to dashboard Cite

Environmental allergen control is recommended as an essential part of allergic rhinitis (AR) management guidelines. In this scoping review, our objective is to identify measures of allergen avoidance and to evaluate their effectiveness in the management of AR. We conducted systematic searches for randomized controlled trials and observational studies in PubMed, the Cochrane Central Register of Controlled Trials, and the Web of Science databases. We included all types of control measures based on allergen eviction or reduction in exposure. Overall, 18 studies satisfied our criteria and were thus included for further analysis. The majority of the studies (15 out of 18) reported decreases in overall AR symptom scores, improvements in quality of life, or reductions in medication usage. However, due to the low number of participants and the limitations in study designs, it is not possible to make a definitive recommendation on the use of these interventions in the management of AR. A multifaceted approach, including treatment, prevention, and eradication of allergens from the environment, may be necessary to effectively reduce symptoms.

show abstract

“…The exclusion criteria were: respiratory infection, uncontrolled asthma, autoimmune diseases, and receipt of immunotherapy or corticosteroids within the past month. All participants were requested to rate the severity of their rhinitis symptoms, including sneezing, nasal congestion, rhinorrhea and nasal itching, using the visual analog scale (score, 0-10) (29). The present study was approved by the Ethics Committee of Renmin Hospital of Wuhan University (approval no.…”

Section: Subjectsmentioning

confidence: 99%

Downregulation of deubiquitinating enzyme USP25 promotes the development of allergic rhinitis by enhancing TSLP signaling in the nasal epithelium

Chang

Tan

et al. 2022

Mol Med Rep

View full text Add to dashboard Cite

Ubiquitin-specific peptidase 25 (USP25) is a key deubiquitylase belonging to the USP superfamily that is primarily involved in inflammation and the immune response. Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that is regarded as the master switch that initiates and maintains the type 2 immune response in allergic rhinitis (AR). However, the molecular mechanisms by which USP25 regulates TSLP signaling in the nasal epithelium in AR remain unclear. The present study assessed the protein expression levels of USP25 in the nasal epithelium of patients with AR. Moreover, USP25 knockout (KO) and wild-type (WT) mice were treated with ovalbumin (OVA) to establish a model of AR. The results of western blotting and immunohistochemistry in the present study demonstrated that the protein expression levels of USP25 were significantly decreased in the nasal mucosa of patients with AR and AR mice, whereas the protein expression levels of TSLP were significantly increased. Allergic inflammation was more severe in USP25 KO mice compared with WT mice exposed to OVA, as demonstrated by increased nose scratching and sneezing, increased eosinophil infiltration, goblet cell hyperplasia and enhanced T helper type 2 (Th2) cytokine production. The results of in vitro experiments demonstrated that silencing or overexpression of USP25 decreased or increased TNF receptor-associated factor 3 (TRAF3) protein expression levels, respectively, in human nasal epithelial cells, whereas TSLP protein expression levels were negatively associated with the expression of USP25 and TRAF3. In summary, USP25 downregulation enhanced TSLP signaling in the nasal mucosal epithelium via decreased TRAF3 expression, thereby exacerbating inflammation in AR. Therefore, USP25 may act as a novel therapeutic target in AR.

show abstract

Allergic Rhinitis Improvement in Asthmatic Children After Using Acaricidal Bait: A Randomized, Double-Blind, Cross-Placebo Study

Cited by 6 publications

References 31 publications

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Avoidance Measures for Patients with Allergic Rhinitis: A Scoping Review

Downregulation of deubiquitinating enzyme USP25 promotes the development of allergic rhinitis by enhancing TSLP signaling in the nasal epithelium

Contact Info

Product

Resources

About